NCT01931761View on ClinicalTrials.gov

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Solid Tumours
Interventions
DRUG

[C14] selumetinib (oral)

Single oral administration \[C14\] 75mg

Trial Locations (1)

Unknown

Research Site, Ruddington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY